Geode Capital Management LLC Purchases 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Geode Capital Management LLC raised its position in UroGen Pharma Ltd. (NASDAQ:URGN) by 8.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 455,637 shares of the company’s stock after acquiring an additional 34,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.94% of UroGen Pharma worth $5,787,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of URGN. RTW Investments LP lifted its stake in shares of UroGen Pharma by 6.5% in the 3rd quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after purchasing an additional 230,000 shares during the period. Great Point Partners LLC increased its holdings in UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after buying an additional 285,714 shares during the last quarter. Point72 Asset Management L.P. raised its position in UroGen Pharma by 120.3% in the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after acquiring an additional 1,337,257 shares during the period. Cowen AND Company LLC boosted its stake in shares of UroGen Pharma by 29.1% during the 2nd quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock worth $35,229,000 after acquiring an additional 472,893 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of UroGen Pharma by 1.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock valued at $17,032,000 after acquiring an additional 21,072 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Trading Up 4.8 %

UroGen Pharma stock opened at $11.21 on Friday. UroGen Pharma Ltd. has a 1 year low of $10.26 and a 1 year high of $20.70. The firm’s 50 day moving average price is $11.73 and its 200-day moving average price is $13.55. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock has a market cap of $262.92 million, a P/E ratio of -3.56 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the prior year, the firm posted ($0.68) earnings per share. On average, equities analysts predict that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Friday, December 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, UroGen Pharma currently has an average rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.